Kiora Pharmaceuticals, Inc.
KPRX
$3.32
$0.03090.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -7.33% | -67.75% | -75.54% | -53.92% | -88.13% |
| Gross Profit | 3,919.41% | 494.15% | 475.62% | 557.18% | 88.13% |
| SG&A Expenses | 18.85% | -8.36% | -16.95% | -31.86% | -35.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.13% | 6.52% | -4.46% | -2.88% | -18.99% |
| Operating Income | 164.22% | 165.41% | 161.80% | 161.89% | 18.99% |
| Income Before Tax | 145.56% | 143.87% | 126.94% | 124.15% | 9.30% |
| Income Tax Expenses | 2,186.82% | 179.91% | 179.91% | 179.91% | 179.91% |
| Earnings from Continuing Operations | 128.73% | 143.55% | 126.45% | 123.62% | 7.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 128.73% | 143.55% | 126.45% | 123.62% | 7.87% |
| EBIT | 164.22% | 165.41% | 161.80% | 161.89% | 18.99% |
| EBITDA | 164.83% | 166.02% | 162.42% | 162.61% | 19.16% |
| EPS Basic | 108.65% | 101.53% | 92.41% | 90.94% | 88.70% |
| Normalized Basic EPS | 115.34% | 103.35% | 98.50% | 94.67% | 89.91% |
| EPS Diluted | 104.00% | 98.40% | 90.96% | 90.08% | 88.70% |
| Normalized Diluted EPS | 109.34% | 99.81% | 97.02% | 93.81% | 89.91% |
| Average Basic Shares Outstanding | 604.44% | 696.12% | 952.02% | 883.05% | 578.91% |
| Average Diluted Shares Outstanding | 650.38% | 762.55% | 1,074.45% | 1,086.79% | 578.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |